Similarly, given their preserved receptor activation capacity, but potentially altered affinity for IGF-binding proteins, including IGFBP-2, it is plausible that high-molecular-weight IGF-II may differentially modulate IGF bioavailability and receptor activation in the glioblastoma microenvironment [258,259]. This evidence concerns the gene IGFBP2 and glioblastoma.